218 related articles for article (PubMed ID: 33519787)
1. A Clofazimine-Containing Regimen Confers Improved Treatment Outcomes in Macrophages and in a Murine Model of Chronic Progressive Pulmonary Infection Caused by the
Lee JM; Park J; Choi S; Jhun BW; Kim SY; Jo KW; Hong JJ; Kim LH; Shin SJ
Front Microbiol; 2020; 11():626216. PubMed ID: 33519787
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Clofazimine as an Alternative for Rifampicin in Mycobacterium avium Complex Pulmonary Disease Treatment: Outcomes of a Randomized Trial.
Zweijpfenning SMH; Aarnoutse R; Boeree MJ; Magis-Escurra C; Stemkens R; Geurts B; van Ingen J; Hoefsloot W
Chest; 2024 May; 165(5):1082-1092. PubMed ID: 38040054
[TBL] [Abstract][Full Text] [Related]
3. Clofazimine as a substitute for rifampicin improves efficacy of
Salillas S; Raaijmakers J; Aarnoutse RE; Svensson EM; Asouit K; van den Hombergh E; Te Brake L; Stemkens R; Wertheim HFL; Hoefsloot W; van Ingen J
Antimicrob Agents Chemother; 2024 Mar; 68(3):e0115723. PubMed ID: 38259101
[No Abstract] [Full Text] [Related]
4. Liposome encapsulation of clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of disseminated Mycobacterium avium-M. intracellulare complex infection.
Mehta RT
Antimicrob Agents Chemother; 1996 Aug; 40(8):1893-902. PubMed ID: 8843300
[TBL] [Abstract][Full Text] [Related]
5. Intracellular and in vivo activities of oxazolidinone drugs against Mycobacterium avium complex infection.
Lee JM; Kim LH; Kim SY; Jhun BW; Lee W; Shin SJ
Sci Rep; 2023 Nov; 13(1):20631. PubMed ID: 37996500
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of clofazimine-containing regimens for treatment of Mycobacterium avium complex-pulmonary disease in patients unsuitable for standard treatment regimen.
Bao S; Chen S; Zheng J; Ma J; Yang J; Huang H; Duan H
Int J Antimicrob Agents; 2024 Feb; 63(2):107061. PubMed ID: 38103753
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of aminoglycosides, clofazimine, d-cycloserine and dapsone against 83 Mycobacterium avium complex clinical isolates.
Huang CC; Wu MF; Chen HC; Huang WC
J Microbiol Immunol Infect; 2018 Oct; 51(5):636-643. PubMed ID: 28705770
[TBL] [Abstract][Full Text] [Related]
8.
Park J; Kim LH; Lee JM; Choi S; Son YJ; Hwang HJ; Shin SJ
Microbiol Spectr; 2023 Aug; 11(5):e0182523. PubMed ID: 37594284
[TBL] [Abstract][Full Text] [Related]
9. A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria.
Ruth MM; Sangen JJN; Remmers K; Pennings LJ; Svensson E; Aarnoutse RE; Zweijpfenning SMH; Hoefsloot W; Kuipers S; Magis-Escurra C; Wertheim HFL; van Ingen J
J Antimicrob Chemother; 2019 Apr; 74(4):935-943. PubMed ID: 30649327
[TBL] [Abstract][Full Text] [Related]
10. Long-term Follow-up of Mycobacterium avium Complex Lung Disease in Patients Treated With Regimens Including Clofazimine and/or Rifampin.
Jarand J; Davis JP; Cowie RL; Field SK; Fisher DA
Chest; 2016 May; 149(5):1285-93. PubMed ID: 26513209
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of antibacterial activity of clofazimine against Mycobacterium avium-Mycobacterium intracellulare complex infection induced by IFN-gamma is mediated by TNF-alpha.
Gomez-Flores R; Tucker SD; Kansal R; Tamez-Guerra R; Mehta RT
J Antimicrob Chemother; 1997 Feb; 39(2):189-97. PubMed ID: 9069539
[TBL] [Abstract][Full Text] [Related]
12. Treatment outcomes of refractory MAC pulmonary disease treated with drugs with unclear efficacy.
Jo KW; Kim S; Lee JY; Lee SD; Kim WS; Kim DS; Shim TS
J Infect Chemother; 2014 Oct; 20(10):602-6. PubMed ID: 24981714
[TBL] [Abstract][Full Text] [Related]
13. Treatment Outcomes of Clofazimine-Containing Regimens in Severe
Lee I; Hwang EJ; Kim JY; Yim JJ; Kwak N
Open Forum Infect Dis; 2024 Feb; 11(2):ofad682. PubMed ID: 38328494
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine.
Field SK; Cowie RL
Chest; 2003 Oct; 124(4):1482-6. PubMed ID: 14555583
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of clofazimine-modified cyclodextrin against Mycobacterium avium complex in human macrophages.
Salem II; Steffan G; Düzgünes N
Int J Pharm; 2003 Jul; 260(1):105-14. PubMed ID: 12818815
[TBL] [Abstract][Full Text] [Related]
16. In vitro activities of rifabutin, azithromycin, ciprofloxacin, clarithromycin, clofazimine, ethambutol, and amikacin in combinations of two, three, and four drugs against Mycobacterium avium.
Yajko DM; Sanders CA; Madej JJ; Cawthon VL; Hadley WK
Antimicrob Agents Chemother; 1996 Mar; 40(3):743-9. PubMed ID: 8851604
[TBL] [Abstract][Full Text] [Related]
17. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection.
Chaisson RE; Keiser P; Pierce M; Fessel WJ; Ruskin J; Lahart C; Benson CA; Meek K; Siepman N; Craft JC
AIDS; 1997 Mar; 11(3):311-7. PubMed ID: 9147422
[TBL] [Abstract][Full Text] [Related]
18. Mycobacterium avium complex infection. Pharmacokinetic and pharmacodynamic considerations that may improve clinical outcomes.
Peloquin CA
Clin Pharmacokinet; 1997 Feb; 32(2):132-44. PubMed ID: 9068928
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of clofazimine as salvage therapy for atypical mycobacterial infection in solid organ transplant recipients.
Cariello PF; Kwak EJ; Abdel-Massih RC; Silveira FP
Transpl Infect Dis; 2015 Feb; 17(1):111-8. PubMed ID: 25620390
[TBL] [Abstract][Full Text] [Related]
20. Role of ethambutol and rifampicin in the treatment of Mycobacterium avium complex pulmonary disease.
Kim HJ; Lee JS; Kwak N; Cho J; Lee CH; Han SK; Yim JJ
BMC Pulm Med; 2019 Nov; 19(1):212. PubMed ID: 31711459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
